https://orcid.org/0000-0002-1286-1858
References
- Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of Pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913.
- Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32(5):e13016.
- Shimizu T, Takebayashi T, Sato Y, et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014;41(11):969–973.
- Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of Pemphigus vulgaris. J Am Acad Dermatol. 2011;65(5):1064–1065.
- Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of Pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151(2):200–203.
- Bhattacharjee R, De D, Handa S, et al. Assessment of the effects of rituximab monotherapy on different subsets of circulating T-regulatory cells and clinical disease severity in severe Pemphigus vulgaris. Dermatology. 2016;232(5):572–577.
- Nili A, Tavakolpour S, Mahmoudi H, et al. Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. Immunopharmacol Immunotoxicol. 2020;42(1):56–58.
- Mahmoudi H, Balighi K, Tavakolpour S, et al. Unexpected worsening of pemphigus vulgaris after rituximab: a report of three cases. Int Immunopharmacol. 2019;71:40–42.